Ivabradine in the treatment of ischemic heart disease - results of the BEUTIFUL study

Abstract

The aim of the BEAUTIFUL clinical trail was to evaluate whether lowering of the heart rate (HR) with the specific sinoatrial node I channels inhibitor ivabradine in patients with stabilized ischemic heart disease (IHD) and left ventricular systolic dysfunction leads to a reduction in cardiovascular mortality and morbidity.

Keywords

• Angina pectoris
• ivabradine
• BEAUTIFUL clinical trial
• heart rate reduction
• cardiovascular mortality and morbiditi